• Journal of Dairy Science and Biotechnology
• /
• 제28권1호
• /
• pp.35-41
• /
• 2010

식품과민반응의 선천적 이력(natural history)과 방어의 이해는 식품 알레르기 환자의 관리에 매우 중요하다. 이러한 주제에 관하여 많은 연구내용들이 완전히 일치하지는 않지만 데이터에서 몇 가지 분명한 교훈을 얻을 수 있다. 첫째, 식품 알레르기는 매우 일반적인 것이다. 둘째, 식품 알레르기의 거의 대부분은 생후 1~2살에 시작한다. 셋째, 모든 식품 알레르기는 일반적으로 긍정적인 결과에 대한 예외가 있지만 증가하고 있는 실정이다. 넷째, 식품 알레르기는 대부분의 어린이들이 시간이 지나면서 없어지지만 일부는 호흡기 알레르기로 발달하여 종종 아토피질환의 시초가 된다. 마지막으로 적어도 몇 가지 식품 알레르기는 유아기와 어린이 시기에 주요 식품알레르겐들을 피함으로써 막을 수 있다.

• IMMUNE NETWORK
• /
• 제22권1호
• /
• pp.5.1-5.22
• /
• 2022

The approval of immunotherapies such as checkpoint inhibitors (CPIs), adoptive cell therapies and cancer vaccines has revolutionized the way cancer treatment is approached. While immunotherapies have improved clinical outcome in a variety of tumor types, some cancers have proven harder to combat using single agents, underscoring the need for multi-targeted immunotherapy approaches. Efficacy of CPIs and cancer vaccines requires patients to have a competent immune system with adequate cell numbers while the efficacy of adoptive cellular therapy is limited by the expansion and persistence of cells after infusion. A promising strategy to overcome these challenges is combination treatment with common gamma-chain cytokines. Gamma-chain cytokines play a critical role in the survival, proliferation, differentiation and function of multiple immune cell types, including CD8 T-cells and NK cells, which are at the center of the anti-tumor response. While the short halflife of recombinant cytokines initially limited their application in the clinic, advancements in protein engineering have led to the development of several next-generation drug candidates with dramatically increased half-life and bioactivity. When combining these cytokines with other immunotherapies, strong evidence of synergy has been observed in preclinical and clinical cancer settings. This promising data has led to the initiation of 70 ongoing clinical trials including IL-2, IL-7, IL-15 and IL-21. This review summarizes the recent advancements of common gamma-chain cytokines and their potential as a cancer immunotherapy.

• IMMUNE NETWORK
• /
• 제14권4호
• /
• pp.171-181
• /
• 2014

Asthma is a common pulmonary disease with several different forms. The most studied form of asthma is the allergic form, which is mainly related to the function of Th2 cells and their production of cytokines (IL-4, IL-5, and IL-13) in association with allergen sensitization and adaptive immunity. Recently, there have been many advances in understanding non-allergic asthma, which seems to be related to environmental factors such as air pollution, infection, or even obesity. Cells of the innate immune system, including macrophages, neutrophils, and natural killer T cells as well as the newly described innate lymphoid cells, are effective producers of a variety of cytokines and seem to play important roles in the development of non-allergic asthma. In this review, we focus on recent findings regarding innate lymphoid cells and their roles in asthma.

• IMMUNE NETWORK
• /
• 제21권3호
• /
• pp.21.1-21.22
• /
• 2021

Myeloid-derived suppressor cells (MDSCs) have strong immunosuppressive activity and are morphologically similar to conventional monocytes and granulocytes. The development and classification of these cells have, however, been controversial. The activation network of MDSCs is relatively complex, and their mechanism of action is poorly understood, creating an avenue for further research. In recent years, MDSCs have been found to play an important role in immune regulation and in effectively inhibiting the activity of effector lymphocytes. Under certain conditions, particularly in the case of tissue damage or inflammation, MDSCs play a leading role in the immune response of the central nervous system. In cancer, however, this can lead to tumor immune evasion and the development of related diseases. Under cancerous conditions, tumors often alter bone marrow formation, thus affecting progenitor cell differentiation, and ultimately, MDSC accumulation. MDSCs are important contributors to tumor progression and play a key role in promoting tumor growth and metastasis, and even reduce the efficacy of immunotherapy. Currently, a number of studies have demonstrated that MDSCs play a key regulatory role in many clinical diseases. In light of these studies, this review discusses the origin of MDSCs, the mechanisms underlying their activation, their role in a variety of clinical diseases, and their function in immune response regulation.

• 한국지능시스템학회논문지
• /
• 제11권2호
• /
• pp.127-131
• /
• 2001

생체 면역시스템은 바이러스나 병원균 등의 외부 침입자로부터 자신을 보호한다. 본 논문에서는 이러한 기능을 컴퓨터 면역시스템에 적용하기 위하여 생체 면역시스템의 기본 요소인 T세포를 모델링 하였다. 모델링한 T세포는 MHC 인식부와 항원 인식부를 가지고 있으며, 매칭을 통하여 컴퓨터내의 랜덤 파일로부터 자기 파일과 비자기 파일을 구분할 수 있다. 모델링한 T세포의 유효성을 보이기 위해서 컴퓨터 바이러스의 문제에 적용하여 자기-비자기 구분이 가능함을 보인다.

• Journal of Microbiology and Biotechnology
• /
• 제32권9호
• /
• pp.1086-1097
• /
• 2022

During the last decades, research and therapeutic methods in cancer treatment have been evolving. As the results, nowadays, cancer patients are receiving several types of treatments, ranging from chemotherapy and radiation therapy to surgery and immunotherapy. In fact, most cancer patients take a combination of current anti-cancer therapies to improve the efficacy of treatment. However, current strategies still cause some side effects to patients, such as pain and depression. Therefore, there is the need to discover better ways to eradicate cancer whilst minimizing side effects. Recently, immunotherapy, particularly immune checkpoint blockade, is rising as an effective anti-cancer treatment. Unlike chemotherapy or radiation therapy, immunotherapy has few side effects and a higher tumor cell removal efficacy depend on cellular immunological mechanisms. Moreover, recent studies suggest that tissue immune responses are regulated by their microbiome composition. Each tissue has their specific microenvironment, which makes their microbiome composition different, particularly in the context of different types of cancer, such as breast, colorectal, kidney, lung, and skin. Herein, we review the current understanding of the relationship of immune responses and tissue microbiome in cancer in both animal and human studies. Moreover, we discuss the cancer-microbiome-immune axis in the context of cancer development and treatment. Finally, we speculate on strategies to control tissue microbiome alterations that may synergistically affect the immune system and impact cancer treatment outcomes.

• Clinical and Experimental Pediatrics
• /
• 제58권7호
• /
• pp.239-244
• /
• 2015

The complement system is part of the innate immune response and as such defends against invading pathogens, removes immune complexes and damaged self-cells, aids organ regeneration, confers neuroprotection, and engages with the adaptive immune response via T and B cells. Complement activation can either benefit or harm the host organism; thus, the complement system must maintain a balance between activation on foreign or modified self surfaces and inhibition on intact host cells. Complement regulators are essential for maintaining this balance and are classified as soluble regulators, such as factor H, and membrane-bound regulators. Defective complement regulators can damage the host cell and result in the accumulation of immunological debris. Moreover, defective regulators are associated with several autoimmune diseases such as atypical hemolytic uremic syndrome, dense deposit disease, age-related macular degeneration, and systemic lupus erythematosus. Therefore, understanding the molecular mechanisms by which the complement system is regulated is important for the development of novel therapies for complement-associated diseases.

• 생약학회지
• /
• 제28권4호
• /
• pp.286-292
• /
• 1997

We studied the screening condition for immune regulatory responsor. We focused on the T-lymphocytes leer this purpose. Mouse fetal thymic organ culture (FTOC) system and flow cytometric analysis were mainly used in this experiment. Even if FTOC is carried out in vivo condition, the pattern of thymic development in the condition of FTOC is similar to that of in vivo condition. In this regard, FTOC system might be very powerful tool to screen the immune regulator, especially concerning on T cells. To establish the optimum condition of FTOC to screen the Immune regulator, we focused on the optimum amount of dose and culture period. The cell number and surface antigens on T cells were also analysed by using hemacytometer and flow cytometer. To monitor the differentiation event, anti-CD3, anti-CD4 and anti-CD8 antibodies were used. Alkoxyglycerol and Phellodendri Cortex were used fur positive and negative control, respectively. Astragalus membranceus was used as test sample. From our analysis, we reached to conclusions that the best dose of extract is $50\;{\mu}g/ml$ of culture medium, the best culture period is for 9 days, and ethanol used as solvent has no toxicity to FTOC.

• BMB Reports
• /
• 제56권12호
• /
• pp.645-650
• /
• 2023

Numerous studies have investigated the cellular prion protein (PrP^C) since its discovery. These investigations have explained that its structure is predominantly composed of alpha helices and short beta sheet segments, and when its abnormal scrapie isoform (PrPSc) is infected, PrPSc transforms the PrP^C, leading to prion diseases, including Creutzfeldt-Jakob disease in humans and bovine spongiform encephalopathy in cattle. Given its ubiquitous distribution across a variety of cellular types, the PrP^C manifests a diverse range of biological functions, including cell-cell adhesion, neuroprotection, signalings, and oxidative stress response. PrP^C is also expressed in immune tissues, and its functions in these tissues include the activation of immune cells and the formation of secondary lymphoid tissues, such as the spleen and lymph nodes. Moreover, high expression of PrP^C in immune cells plays a crucial role in the pathogenesis of prion diseases. In addition, it affects inflammation and the development and progression of cancer via various mechanisms. In this review, we discuss the studies on the role of PrP^C from various immunological perspectives.

• 한국지능시스템학회논문지
• /
• 제14권6호
• /
• pp.699-704
• /
• 2004

본 논문에서는 인공 면역 시스템과 분류자 시스템에 기반하여 동작하는 자율분산로봇 시스템을 제안한다. 시스템에서 로봇들의 행동은 전역행동과 지역행동으로 분류된다. 전역행동은 환경에서 작업을 탐색하는데 이를 빠르게 수행하기 위하여 집합과 분산의 두 가지 행동으로 이루어져 있다 이때 인공 면역 시스템은 로봇이 어떤 행동을 선택하여 행동할 것인가를 결정한다. 지역행동은 탐색된 작업을 수행하는 부분으로서 어떤 로봇들이 협조행동을 할지를 학습하고, 학습한 결과에 따라 작업을 수행하는 행동을 한다. 이를 위해 분류자 시스템을 이용하여 각 로봇들은 주어진 작업에 대하여 학습을 한다. 제안된 시스템에서 학습 알고리즘은 주어지는 작업의 변화로봇들은 주어진 작업을 수행하기 위해 학습을 하고, 주어진 작업이 변할 경우 스스로 대처한다는 면에서 기존의 자율 분산 시스템보다 적응성에서 향상된 시스템이다.